c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma

Blasco, Rafael B., Francoz, Sarah, Santamaría, David, Cañamero, Marta, Dubus, Pierre, Charron, Jean, Baccarini, Manuela, Barbacid, Mariano·2011·Cancer Cell
DOI 10.1016/j.ccr.2011.04.002

Cited by (305)

Items 201–300 of 305

  1. The Fanconi anemia pathway controls oncogenic response in hematopoietic stem and progenitor cells by regulating PRMT5-mediated p53 arginine methylation
    Wei Du, Surya P. Amarachintha, Ozlem Erden, Andrew Wilson, Qishen Pang · 2016 · Oncotarget
  2. Synthetic Vulnerabilities in the KRAS Pathway
    Marta Román, Elizabeth E. Hwang, Alejandro Sweet-Cordero · 2022 · Cancers
  3. Ku70 senses cytosolic DNA and assembles a tumor-suppressive signalosome
    Abhimanu Pandey, Cheng Xing Shen, Shouya Feng, Daniel Enosi Tuipulotu, Chinh Ngo, Cheng Liu, Melan Kurera, Anukriti Mathur, Shweta Venkataraman, Jing Zhang et al. · 2024 · Science Advances
  4. Genetic analysis of Ras genes in epidermal development and tumorigenesis
    Matthias Drosten, Carmen G. Lechuga, Mariano Barbacid · 2013 · Small GTPases
  5. Discovery of the First-in-Class Mek Inhibitor Trametinib (Trade Name: Mekinist) and Other Molecular Targeting Agents by “Rb-Reactivator Screening”
    Toshiyuki Sakai · 2022 · Pharmacology & Therapeutics
  6. Phosphoproteomics reveals the BRAF-ERK1/2 axis as an important pathogenic signaling node in cartilage degeneration
    Yonghui Dong, Ping Wang, M. Zhang, Lan Xiao, Yong‐Guang Yang, Binghua Wang, Ying Liu, Z. Dai, Jia Zheng · 2022 · Osteoarthritis and Cartilage
  7. Elimination of B-RAF in Oncogenic C-RAF-expressing Alveolar Epithelial Type II Cells Reduces MAPK Signal Intensity and Lung Tumor Growth
    Emanuele Zanucco, Nefertiti Adly El-Nikhely, Rudolf Götz, Katharina Weidmann, Verena Pfeiffer, Rajkumar Savai, Werner Seeger, Axel Ullrich, Ulf Rüdiger Rapp · 2014 · Journal of Biological Chemistry
  8. Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations
    Rekha Pal, Ning Wei, Nan Song, Shaoyu Wu, Rim S. Kim, Ying Wang, Patrick G. Gavin, Peter C. Lucas, Ashok Srinivasan, Carmen Joseph Allegra et al. · 2018 · PLoS ONE
  9. Non‐canonical Raf‐1/p70S6K signalling in non–small‐cell lung cancer
    Zhixin Qiu, Bingwei Ye, Shuang Zhao, Xin Li, Lei Li, Xi-ming Mo, Weimin Li · 2019 · Journal of Cellular and Molecular Medicine
  10. Phase I/II RAF kinase inhibitors in cancer therapy
    Samra Turajlic, Zohra Ali, Nadia Yousaf, James Larkin · 2013 · Expert Opinion on Investigational Drugs
  11. Inhibitors of the ERK mitogen-activated protein kinase cascade for targeting RAS mutant cancers.
    Leanna R. Gentry, A. Samatar, C. Der · 2013 · The Enzymes
  12. Virtual screening, pharmacokinetic, and DFT studies of anticancer compounds as potential kinase inhibitors
    Abdullahi Bello Umar, Adamu Uzairu · 2023 · Journal of Taibah University Medical Sciences
  13. New Insight Puts CRAF in Sight as a Therapeutic Target
    Ana Paula Rebocho, Richard Marais · 2011 · Cancer Discovery
  14. Three distinct regions of cRaf kinase domain interact with membrane
    Priyanka Prakash, John F. Hancock, Alemayehu Abebe Gorfe · 2019 · Scientific Reports
  15. An RNAi-based system for loss-of-function analysis identifies Raf1 as a crucial mediator of BCR-ABL–driven leukemogenesis
    Corinna Albers, Anna Lena Illert, Cornelius Miething, Hannes Leischner, Melanie Thiede, Christian Peschel, Justus Duyster · 2011 · Blood
  16. Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal Adenocarcinoma
    Navid Sobhani, Matteo Pittacolo, Alberto D’Angelo, Giovanni Marchegiani · 2025 · Cancers
  17. Harnessing G-quadruplex ligands for lung cancer treatment: A comprehensive overview
    Joana Figueiredo, Mojgan Djavaheri‐Mergny, Lucille Ferret, Jean‐Louis Mergny, Carla Cruz · 2023 · Drug Discovery Today
  18. Vav1 accelerates Ras-driven lung cancer and modulates its tumor microenvironment.
    Batel Shalom, Marganit Farago, Yaser Salaymeh, Shulamit Sebban, Matan Risling, Eli Pikarsky, Shulamit Katzav · 2022 · Cellular Signalling
  19. ERK1 as a Therapeutic Target for Dendritic Cell Vaccination against High-Grade Gliomas
    Min‐Chi Ku, Inan Edes, Ivo Bendix, Andreas Pohlmann, Helmar Waiczies, Tim Prozorovski, Martin Günther, Conrad Martin, Gilles Pagès, Susanne A. Wolf et al. · 2016 · Molecular Cancer Therapeutics
  20. Exceptional Response to MEK Inhibition in a Patient With RAF1-Mutant Myxofibrosarcoma: Case Report and Mechanistic Overview
    Eylül Özgü, Esranur Aydın, Ashkan Adibi, Ünal Metin Tokat, Onur Tutar, Jiancheng Hu, İrem Demiray, Razelle Kurzrock, Mutlu Demiray · 2023 · JCO Precision Oncology
  21. Persistent DNA damage and oncogenic stress-induced Trem1 promotes leukemia in mice
    Xue Li, Srinivas Chatla, Andrew F. Wilson, Limei Wu, Neha Atale, Wei Du · 2022 · Haematologica
  22. Rapid onset lung squamous cell carcinoma with prominent peritoneal carcinomatosis and an eosinophilic leukemoid reaction, with coexistence of the BRAF V600E and oncogenic KRAS G12A mutations: A case report
    Bin Li, Jing Lu, Dan He, Jun Wang, Hui Zhou, Liangfang Shen, Chunfang Zhang, Chaojun Duan · 2014 · Oncology Letters
  23. Opening a New GATAway for Treating KRAS-Driven Lung Tumors
    Mariano Barbacid · 2012 · Cancer Cell
  24. Notching up a new therapeutic strategy for Non-Small Cell Lung Carcinoma (NSCLC)
    Antonio Maraver, Manuel Serrano · 2012 · Oncotarget
  25. Peptide inhibitors targeting Ras and Ras-associated protein–protein interactions
    Dan Han, Anpeng Li, Lie Zhu, Chunlin Zhuang, Qingjie Zhao, Yan Zou · 2024 · European Journal of Medicinal Chemistry
  26. The steady progress of targeted therapies, promising advances for lung cancer
    Lorenzo Bombardelli, Anton J. M. Berns · 2016 · ecancermedicalscience
  27. Context Matters—Why We Need to Change From a One Size Fits all Approach to Made-to-Measure Therapies for Individual Patients With Pancreatic Cancer
    Sushmitha Sankarasubramanian, Ulrike Pfohl, Christian R. A. Regenbrecht, Christoph Reinhard, Lena Wedeken · 2021 · Frontiers in Cell and Developmental Biology
  28. Genetically Engineered Mouse Models for Human Lung Cancer
    Kazushi Inoue, Elizabeth A. Fry, Dejan Maglic, Sinan Zhu · 2013 · InTech eBooks
  29. A Systems Biology Approach to Personalizing Therapeutic Combinations
    Lawrence N. Kwong, Timothy Paul Heffernan, Lynda Chin · 2013 · Cancer Discovery
  30. Enzyme meets a surprise target
    Marian M. Deuker, Martin McMahon · 2014 · Nature
  31. Cysts mark the early stage of metastatic tumor development in non-small cell lung cancer
    Chitra Thakur, Ulf Rüdiger Rapp, Thomas Rudel · 2017 · Oncotarget
  32. RAF1 kinase contributes to autophagic lysosome reformation
    Stefanie Toifl, Sebastian Didusch, Karin Ehrenreiter, Enrico Desideri, Coralie Dorard, Manuela Baccarini · 2025 · Cell Reports
  33. Ras proteins as therapeutic targets
    Atanu Chakraborty, Emily Linnane, Sarah J. Ross · 2018 · Biochemical Society Transactions
  34. Токсичність МАРК у карциномах щитоподібної залози. Механізми пригнічення сигнального каскаду (огляд літератури та власних даних)
    B.B. Guda, VIKTOR V. PUSHKAREV, О.І. Ковзун, V. P. Pushkarev, Mykola D. Tronko · 2019 · Шпитальна хірургія Журнал імені Л Я Ковальчука
  35. SIRT4 as a novel interactor and candidate suppressor of C-RAF kinase in MAPK signaling
    Mehrnaz Mehrabipour, Saeideh Nakhaei‐Rad, Radovan Dvorský, Alexander Lang, Patrick Verhülsdonk, Mohammad Reza Ahmadian, Roland P. Piekorz · 2024 · Life Science Alliance
  36. Progress in Targeting KRAS Directly
    Dwight V. Nissley, Andrew G. Stephen, Ming Yi, Frank P. McCormick · 2024 · Methods in molecular biology
  37. Oncogenesis, Inflammatory and Parasitic Tropical Diseases of the Lung
    Jean-Marie Kayembe · 2013 · InTech eBooks
  38. Stress Kinase Signaling in Cardiac Myocytes
    Xun Ai, Jiajie Yan, Dan J. Bare · 2022 · Springer eBooks
  39. Targeting the Raf-MEK-ERK Mitogen-Activated Protein Kinase Cascade for the Treatment of RAS Mutant Cancers
    Tikvah K. Hayes, Channing J. Der · 2014 · Springer eBooks
  40. NRAS-driven melanoma: A RAF can hide another
    Sabine Druillennec, Célio Pouponnot, Alain Eychène · 2017 · Molecular & Cellular Oncology
  41. Oncogene toxicity in thyroid carcinomas and other types of tumors
    V.M. Pushkarev, B.B. Guda, V. V. Pushkarev, Mykola D. Tronko · 2018 · Cytology and Genetics
  42. The Increasing Diversity of KRAS Signaling in Pancreatic Cancer
    Jens Thomas Siveke · 2014 · Gastroenterology
  43. Design, synthesis, and antitumor activity of stapled peptide inhibitors targeting the RAS–RAF interactions
    Dan Han, Yu Zhou, Kai Zhang, Conghao Gai, Peichao Zhang, Xiaoyun Chai, Xiaobing Zhuo, Qingjie Zhao, Yan Zou, Lie Zhu · 2025 · European Journal of Medicinal Chemistry
  44. Erk1R84H is an oncoprotein that causes hepatocellular carcinoma in mice and imposes a rigorous negative feedback loop
    Nadine Soudah, Alexey Baskin, Merav Darash‐Yahana, Ilona Darlyuk‐Saadon, Karina Smorodinsky-Atias, Tali Shalit, Weiping Yu, Alon Savidor, Eli Pikarsky, David Engelberg · 2025 · Oncogene
  45. Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors
    Jiawan Wang, Arnab Sarkar, Natalia García, Lindy Zhang, Ana Calizo, Alla Lisok, Katia Campos, Funan He, Nishanth Punjaala, Teresa C Marple et al. · 2025 · Molecular Medicine
  46. The RAS Signaling Network and Cancer
    Priya S. Hibshman, Channing J. Der · 2024 · Springer eBooks
  47. Challenging Roadblocks to Cancer Cure
    Massimo F. Loda · 2016 · Cancer Research
  48. Molecular pathological findings of Merkel cell polyomavirus in lung cancer: A possible etiopathogenetic link?
    Katerina M. Antoniou, Ismini Lasithiotaki, Emmanouil K. Symvoulakis, Stavros Derdas, Anna Psaraki, Demetrios A. Spandidos, Efstathios N. Stathopoulos, Nikolaos M. Siafakas, George Sourvinos · 2013 · International Journal of Cancer
  49. Differential contribution for ERK1 and ERK2 kinases in BRAFV600E-triggered phenotypes in adult mouse models
    Giuseppe Bosso, Ana Carolina Cintra Herpst, Oscar Laguía, Sarah Adetchessi, Rosa Serrano, Marı́a A. Blasco · 2024 · Cell Death and Differentiation
  50. Recent advances in targeted degradation in the RAS pathway
    Zhiming Ge, Zisheng Fan, Wei He, Guizhen Zhou, Yidi Zhou, Mingyue Zheng, Sulin Zhang · 2025 · Future Medicinal Chemistry
  51. Deciphering the universe of genetic context-dependencies using mouse models of cancer
    Chiara Falcomatà, Stefanie Bärthel, Günter Schneider, Dieter Saur, Christian Veltkamp · 2019 · Current Opinion in Genetics & Development
  52. Mice as Experimental Organisms
    Giorgio Roberto Merlo, Fiorella Altruda, Valeria Poli · 2012 · Encyclopedia of Life Sciences
  53. Signaling in hepatocellular carcinoma
    Adam Pennycuick, Augusto Villanueva · 2015
  54. The Use of Genetically Modified Animals in Discovery Toxicology
    Dolores Diaz, Jonathan M. Maher · 2016
  55. Targeting small GTPases and their downstream pathways with intracellular macromolecule binders to define alternative therapeutic strategies in cancer
    Marie Sorbara, Nicolas Béry · 2021 · Biochemical Society Transactions
  56. RAF1 as a standalone therapeutic target in KRAS-driven lung adenocarcinoma: No added efficacy from co-targeting ARAF, EGFR, or DDR1
    Laura de la Puente Ovejero, Ana Fernández-Rodríguez, Sarah Francoz, Gonzalo Aizpurua, Lucia Lomba-Riego, Matthias Drosten, Carmen Guerra, Mónica Musteanu, Mariano Barbacid, Sara García‐Alonso · 2026 · PLoS ONE
  57. Disruption of the pro-oncogenic c-RAF–PDE8A complex represents a differentiated approach to treating KRAS–c-RAF dependent PDAC
    Sean F Cooke, Thomas A. Wright, Yuan Yan Sin, Jiayue Ling, Elka Kyurkchieva, Nattaporn Phanthaphol, Thomas Mcskimming, Katharine J. Herbert, Selma Rebus, Andrew Victor Biankin et al. · 2024 · Scientific Reports
  58. Biochemical Pathways in Cancer
    Eun-Kyoung Yim Breuer, Mandi M. Murph, Rolf J. Craven · 2012 · Biochemistry Research International
  59. Exploiting c-RAF dependency in RAS mutant cancer: beyond catalytic activity
    Sean F Cooke, Connor M. Blair · 2024 · Expert Review of Anticancer Therapy
  60. The repressor Capicua is a barrier to lung tumor development driven by Kras/Trp53 mutations
    Irene Ballesteros-González, Ivan Hernández-Navas, Oksana Brehey, Carmen G. Lechuga, Marina Salmón, Morena Scotece, Ricardo Velasco-Vicente, Alejandra A. Flores-Gómez, Antonio Cebriá, Lucía Simón-Carrasco et al. · 2025 · EMBO Molecular Medicine
  61. CRAF, acteur-clé dans les adénocarcinomes pulmonaires induits par l’oncogène K-Ras
    Sarah Francoz, Pierre R. Dubus · 2011 · médecine/sciences
  62. The Expression, Purification, and Characterization of a Ras Oncogene (Bras2) in Silkworm (Bombyx mori)
    Zhengbing Lv, Tao Wang, Wenhua Zhuang, Dan Wang, Jian Chen, Zuoming Nie, Lili Liu, Wenping Zhang, Lisha Wang, Deming Wang et al. · 2013 · International Journal of Genomics
  63. Progress in Targeting RAF Kinases for Cancer Therapy
    Thomas J. Turbyville, Matthew T. Holderfield · 2015 · Personalized Medicine
  64. Partners in Crime: Clandestine Operations among RAS-RAF Accomplices in Promoting Tumorigenesis
    Avinashnarayan Venkatanarayan, Shiva Malek · 2019 · Molecular Cell
  65. Quo vadis, Kras?
    Günter Schneider, Dieter Saur · 2013 · Oncotarget
  66. Investigation of KRAS Dependency Bypass and Functional Characterization of All Possible KRAS Missense Variants
    Seav Huong Ly · 2018 · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
  67. Data from Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy
    Jesse Boumelha, Míriam Molina‐Arcas, Julian Downward · 2023
  68. Modèles précliniques chez le rongeur de carcinomes pulmonaires
    Sarah Francoz, Juliette Mathiaux, Pierre R. Dubus · 2012 · Bulletin du Cancer
  69. IN FOCUS A Systems Biology Approach to Personalizing Therapeutic Combinations
    Lawrence N. Kwong, Timothy Paul Heffernan, Lynda Chin · 2013
  70. Efficacy of organic nanocarriers in a 3D colorectal cancer in vitro model
    V Lopez Davila · 2015 · UCL Discovery (University College London)
  71. Next-Generation Strategies to Target RAF
    Darrin D. Stuart · 2016 · Elsevier eBooks
  72. TARGETING THE ERK MAPK PATHWAY IN RAS-DRIVEN CANCERS
    Meagan B. Ryan · 2019 · Carolina Digital Repository (University of North Carolina at Chapel Hill)
  73. Drug Repurposing Screen on Patient-Derived Organoids Identifies New Therapeutic Drug Combination Against KRAS Mutant Colon Cancer
    Sander Mertens, Carla S. Veríssimo, Bas Ponsioen, Maarten A. Huismans, Jeanine M.L. Roodhart, Maarten A. Huismans, René Overmeer, Natalie Proost, Olaf van Tellingen, Marieke van de Ven et al. · 2021 · SSRN Electronic Journal
  74. KRAS G12D can be targeted by potent salt-bridge forming inhibitors
    Zhongwei Mao, Hongying Xiao, Panpan Shen, Yu Yang, Jing Wen Xue, Yunyun Yang, Yanguo Shang, Lilan Zhang, Xin Li, Yuying Zhang et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  75. Discovery of the First-in-Class Mek Inhibitor Trametinib (Trade Name: Mekinist) and Other Molecular Targeting Agents by “Rb-Reactivator Screening”
    Toshiyuki Sakai · 2022 · SSRN Electronic Journal
  76. Therapeutic Targeting of MEK1/2 Synergizes with PARP1 Inhibitors in the Treatment of Malignant Pleural Mesothelioma
    Haitang Yang, Yanyun Gao, Duo Xu, Shun‐Qing Liang, Yang Zhang, Amina Scherz, Sean R. R. Hall, Stefan Forster, Sabina Berezowska, Feng Yao et al. · 2022 · SSRN Electronic Journal
  77. The Design, Synthesis, and Evaluation of Evodiamine Derivatives with Hydroxy Groups
    Zheng Yang, Hui Guo, Keyao Zhang, Zebo Jiang, Ruyi Jin, Dongyan Guo, Zhi Li, Yuwei Wang, Lingjie Meng · 2022 · Letters in Drug Design & Discovery
  78. Data from Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition
    Liang Yan, Bo Tu, Jun Yao, Jing Gong, Alessandro Carugo, Christopher Aaron Bristow, Qiuyun Wang, Cihui Zhu, Bingbing Dai, Ya’an Kang et al. · 2023
  79. Table S8 from LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors
    Kelli‐Ann Monaco, Scott M. Delach, Jing Yuan, Yuji M. Mishina, Paul Fordjour, Emma Labrot, Daniel McKay, Ribo Guo, Stacy E. Higgins, Hui Qin Wang et al. · 2023
  80. Data from LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors
    Kelli‐Ann Monaco, Scott M. Delach, Jing Yuan, Yuji M. Mishina, Paul Fordjour, Emma Labrot, Daniel McKay, Ribo Guo, Stacy Higgins, Hui Qin Wang et al. · 2023
  81. Supplementary Figure from Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition
    Liang Yan, Bo Tu, Jun Yao, Jing Gong, Alessandro Carugo, Christopher Aaron Bristow, Qiuyun Wang, Cihui Zhu, Bingbing Dai, Ya’an Kang et al. · 2023
  82. Data from Vertical Inhibition of the RAF–MEK–ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRASQ61X Mutant Rhabdomyosarcoma
    Natalia García, Vanessa Del Pozo, Marielle E. Yohe, Craig M. Goodwin, Terry J. Shackleford, Long Wang, Kunal Baxi, Yidong Chen, Anna T. Rogojina, Sara M. Zimmerman et al. · 2023
  83. Data from Vertical Inhibition of the RAF–MEK–ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRASQ61X Mutant Rhabdomyosarcoma
    Natalia García, Vanessa Del Pozo, Marielle E. Yohe, Craig M. Goodwin, Terry J. Shackleford, Long Wang, Kunal Baxi, Yidong Chen, Anna T. Rogojina, Sara M. Zimmerman et al. · 2023
  84. Target Hyperactive ERK Signaling for Cancer Therapy
    Jiajun Yap, Jiancheng Hu · 2023 · Springer eBooks
  85. Identification of SIRT4 as a novel paralog-specific interactor and candidate suppressor of C-RAF kinase in MAPK signaling
    Mehrnaz Mehrabipour, Radovan Dvorský, Saeideh Nakhaei‐Rad, Alexander Lang, Patrick Verhülsdonk, Mohammad Reza Ahmadian, Roland P. Piekorz · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  86. Data from Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy
    Jesse Boumelha, Míriam Molina‐Arcas, Julian Downward · 2023
  87. Mitochondrial Raf1 Regulates Glutamine Catabolism
    Ronald L. Shanderson, Ian Ferguson, Zurab Siprashvili, Luca Ducoli, Albert Mao Li, Weili Miao, Suhas Srinivasan, Mary Grace M. Velasco, Yang Li, Jiangbin Ye et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  88. Bioluminescence Resonance Energy Transfer (BRET)-based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells
    Russell Spencer-Smith · 2024 · Journal of Visualized Experiments
  89. Mediating kinase activity in Ras-mutant cancer: potential for an individualised approach?
    Fiona M. Healy, Amy L. Turner, Vanessa Marensi, David J. MacEwan · 2024 · Frontiers in Pharmacology
  90. RAS Family Interactions: The SHOC2-MRAS-PP1 Complex in Noonan Syndrome
    Isabel Boned del Río, Pablo Rodriguez‐Viciana · 2024 · Springer eBooks
  91. Design, Synthesis, and Antitumor Activity of Stapled Peptide Inhibitors Targeting the Ras–Raf Interactions
    Yan Zou, Dan Han, Yu Zhou, Kai Zhang, Conghao Gai, Peichao Zhang, Xiaoyun Chai, Xiaobin Zhuo, Qingjie Zhao, Lie Zhu · 2025 · SSRN Electronic Journal
  92. The mechanism of E3 ubiquitin ligase HERC1 regulating ferroptosis in lung adenocarcinoma cells
    Fei Ye, Yi Xu, Xujuan Zhu, Qifeng Ding, Yifei Wang, Songhua Lu, Yongbing Chen · 2025 · Cancer Genetics
  93. Target Hyperactive ERK Signaling for Cancer Therapy
    Jiajun Yap, Jiancheng Hu · 2025 · Springer eBooks
  94. Discovery of potent KRASG12D inhibitors disrupting RAS-Raf interaction to block activation
    Zhaoyang Li, Junru Liu, Yingying Yan, Xiujuan Shi, Benlong Cao, Y. Lynn Wang, Fuxun Huang, Jingtong Feng, Qingqiang Yao, Bo Liu et al. · 2026 · Results in Chemistry
  95. ERKed by too much signaling: from oncogenic driver to therapeutic vulnerability
    D. Farnsworth, F. Naznin, A. Subramaniam, K. Sew, William W. Lockwood · 2026 · Cellular and Molecular Life Sciences (CMLS)
  96. MiR-4510 suppresses hepatocellular carcinoma development through RAF1 targeting and MAPK/ERK signaling inhibition
    Amani Ghousein · 2018 · theses.fr (ABES)
  97. Rôle de la kinase ARAF dans le mélanome cutané muté NRAS
    Charlène Estrada · 2020 · theses.fr (ABES)
  98. Hsp90 Inhibition on the Western Blot: N‐Terminal Versus C‐Terminal Inhibitors in Breast Cancer
    Jaka Dernovšek, Jernej Cingl, Urša Pečar Fonović, Tihomir Tomašič · 2026 · Medicinal Research Reviews
  99. The absorption, distribution, metabolism, excretion, and pharmacokinetic properties of the pan–rapidly accelerated fibrosarcoma (RAF) inhibitor naporafenib in healthy subjects: An absolute bioavailability and mass balance study
    Justine L. Lam, Zhangzhou Shen, Alfin D. N. Vaz, Roxana Picard, Ai Ling Ching, Shinji Fujimori, Xiaoying Chen, Dawei Xuan · 2026 · Drug Metabolism and Disposition
  100. Mitochondrial Raf1 regulates glutamine catabolism
    Ronald L. Shanderson, Ian Ferguson, Luca Ducoli, Weili Miao, Suhas Srinivasan, Zurab Siprashvili, Albert Mao Li, Mary Grace M. Velasco, Yang Li, Christine N. Hoang et al. · 2026 · Cell Reports